VERU INC. 8K

Veru Inc. announced fiscal 2026 first quarter results and a corporate update, including strengthened cash, narrowed losses, FDA guidance on enobosarm’s obesity program, and the planned start of its Phase 2b PLATEAU trial in early 2026.

On February 11, 2026, Veru Inc. reported its fiscal 2026 first quarter financial results for the period ended December 31, 2025, highlighting significantly reduced research and development and general and administrative expenses that lowered its net loss to $5.3 million and increased cash and equivalents to $33.0 million, while also providing a corporate update on its obesity drug candidate enobosarm, including positive regulatory feedback from the FDA on potential approval pathways in combination with GLP‑1 receptor agonists, the design and planned initiation in the first quarter of calendar 2026 of the Phase 2b PLATEAU clinical trial with an interim analysis expected in the first quarter of calendar 2027, and the prior positive results and ongoing scientific dissemination of data from its Phase 2b QUALITY study and maintenance extension in older patients with obesity on semaglutide.

Filing Facts

CIK

863894

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-045527

Alert Tier

6